Division of Experimental Oncology, Multidisciplinary Oncology Center (CePO), Lausanne, Switzerland.
J Biol Chem. 2012 Jun 29;287(27):23068-78. doi: 10.1074/jbc.M112.357673. Epub 2012 May 1.
Through a rational design approach, we generated a panel of HLA-A*0201/NY-ESO-1(157-165)-specific T cell receptors (TCR) with increasing affinities of up to 150-fold from the wild-type TCR. Using these TCR variants which extend just beyond the natural affinity range, along with an extreme supraphysiologic one having 1400-fold enhanced affinity, and a low-binding one, we sought to determine the effect of TCR binding properties along with cognate peptide concentration on CD8(+) T cell responsiveness. Major histocompatibility complexes (MHC) expressed on the surface of various antigen presenting cells were peptide-pulsed and used to stimulate human CD8(+) T cells expressing the different TCR via lentiviral transduction. At intermediate peptide concentration we measured maximum cytokine/chemokine secretion, cytotoxicity, and Ca(2+) flux for CD8(+) T cells expressing TCR within a dissociation constant (K(D)) range of ∼1-5 μM. Under these same conditions there was a gradual attenuation in activity for supraphysiologic affinity TCR with K(D) < ∼1 μM, irrespective of CD8 co-engagement and of half-life (t(1/2) = ln 2/k(off)) values. With increased peptide concentration, however, the activity levels of CD8(+) T cells expressing supraphysiologic affinity TCR were gradually restored. Together our data support the productive hit rate model of T cell activation arguing that it is not the absolute number of TCR/pMHC complexes formed at equilibrium, but rather their productive turnover, that controls levels of biological activity. Our findings have important implications for various immunotherapies under development such as adoptive cell transfer of TCR-engineered CD8(+) T cells, as well as for peptide vaccination strategies.
通过合理的设计方法,我们从野生型 TCR 产生了一组 HLA-A*0201/NY-ESO-1(157-165)-特异性 T 细胞受体 (TCR),其亲和力高达 150 倍。使用这些 TCR 变体,其亲和力超出了自然亲和力范围,以及一个具有 1400 倍增强亲和力的超生理亲和力,以及一个低亲和力的 TCR,我们试图确定 TCR 结合特性以及同源肽浓度对 CD8(+) T 细胞反应性的影响。各种抗原呈递细胞表面表达的主要组织相容性复合物 (MHC) 被肽脉冲,并通过慢病毒转导用于刺激表达不同 TCR 的人 CD8(+) T 细胞。在中间肽浓度下,我们测量了表达 TCR 的 CD8(+) T 细胞的最大细胞因子/趋化因子分泌、细胞毒性和 Ca(2+) 流,TCR 的解离常数 (K(D)) 范围约为 1-5 μM。在相同条件下,具有 K(D) < ∼1 μM 的超生理亲和力 TCR 的活性逐渐减弱,无论 CD8 共结合和半衰期 (t(1/2) = ln 2/k(off)) 值如何。然而,随着肽浓度的增加,表达超生理亲和力 TCR 的 CD8(+) T 细胞的活性水平逐渐恢复。我们的数据共同支持 T 细胞激活的有效命中率模型,该模型表明,控制生物学活性水平的不是在平衡时形成的 TCR/pMHC 复合物的绝对数量,而是它们的有效周转率。我们的发现对正在开发的各种免疫疗法具有重要意义,例如 TCR 工程化 CD8(+) T 细胞的过继细胞转移,以及肽疫苗接种策略。